Mounjaro and cancer risks: what the current evidence shows

You've read that GLP-1 medicines can cause thyroid cancer. Here is what that actually refers to.

The thyroid cancer concern originates from pre-clinical studies done in rodents, not from human trial data. At very high, sustained doses, some GLP-1 receptor agonists caused C-cell tumours in rat and mouse thyroid tissue. C-cells are responsible for producing calcitonin, and tumours arising from them are called medullary thyroid carcinomas. The findings were significant enough that the Mounjaro Summary of Product Characteristics (SmPC) on the eMC carries a clear contraindication: Mounjaro must not be used by anyone with a personal or family history of MTC or MEN2.

Crucially, rodent thyroid C-cells express GLP-1 receptors at far higher density than human thyroid C-cells do. That biological difference is why regulators and researchers do not expect a direct translation to humans. Across the major tirzepatide clinical trials, including the large SURMOUNT programme involving thousands of adults with obesity, no increased rate of thyroid cancer was observed in the human participants. If you want to understand exactly what the evidence says, our page on Mounjaro cancer risk sets out the research in detail, covering both what has and has not been observed in human data. The contraindication remains on precautionary grounds, not because human evidence has confirmed harm. That is an important distinction.

Tirzepatide also activates GIP receptors, which GLP-1-only medicines do not. GIP receptor signalling in thyroid tissue is less well characterised, so this remains an area of active scientific interest rather than a settled finding.

What about other cancer signals that have come up in research?

Beyond the thyroid, researchers have examined whether GLP-1 medicines affect rates of pancreatic cancer, given that acute pancreatitis is a known risk with this drug class. The MHRA flagged pancreatitis explicitly in its January 2026 Drug Safety Update covering GLP-1 medicines. Chronic pancreatitis is a recognised risk factor for pancreatic cancer, so the theoretical chain exists. However, clinical trial data from tirzepatide and the broader GLP-1 class have not shown a statistically significant increase in pancreatic cancer in treated participants compared with placebo groups. Our dedicated page on Mounjaro side effects and cancer walks through each of these signals and explains how regulators have interpreted them so far.

There is also an emerging body of observational data suggesting that significant weight loss may itself be protective against several obesity-related cancers, including endometrial, colorectal and breast cancers. The question of whether Mounjaro may reduce certain cancer risks through weight loss is genuinely being studied. Some early observational analyses are encouraging, but they are not yet mature enough to translate into clinical claims, and long-term randomised data are still being gathered.

The current position of regulators is neither alarm nor reassurance: it is active monitoring. Post-marketing surveillance, registries, and long-term follow-up studies are collecting real-world data. That is exactly what the Black Triangle (▼) designation on Mounjaro's licence signals.

When to get medical help, and what to watch for

Most people taking Mounjaro experience gastrointestinal side effects rather than anything cancer-related. But there are specific symptoms that warrant prompt medical attention and should not be attributed to the medicine without proper assessment. Contact a doctor or NHS 111 promptly if you notice any of the following while taking Mounjaro: a new lump or swelling in the neck, persistent hoarseness or a change in your voice, difficulty swallowing, shortness of breath, or severe abdominal pain that radiates to the back (which can signal pancreatitis). These symptoms are listed in the patient information leaflet for good reason. None of them necessarily indicate cancer, but they need proper evaluation.

Routine monitoring of calcitonin levels is not standard practice in the UK for people taking GLP-1 medicines without a relevant history, but this is something a prescriber can discuss with you individually. If you have a family history of thyroid conditions or have had any previous thyroid surgery, make sure this is declared clearly during your consultation. You may also find it helpful to read about the Mounjaro blindness risk, which is another area where understanding who is most affected helps put the overall safety profile in context. A prescriber reading your notes carefully is the first line of safety here.

Side effects of any kind, including unexpected ones, can be reported directly to the MHRA via the Yellow Card scheme. That reporting system is how post-marketing safety signals are identified in the UK, and patient reports genuinely contribute to it. The NHS medicines page for tirzepatide also lists side effects and the circumstances that require urgent attention.

How nume approaches cancer-related safety in your consultation

Every prescription issued through our pharmacy follows a same-day review by a real prescriber, your answers are read, not processed by a decision tree. Cancer history, family history of MTC or MEN2, and any current oncology treatment are explicit points of clinical assessment, not optional boxes to tick. If a prescriber has questions, they ask them. If there is a genuine contraindication, the prescription is not issued.

If you are currently in remission from cancer or undergoing treatment, the right starting point is a conversation with your oncologist before adding any new medicine. That is not a barrier specific to Mounjaro; it applies to any prescription medicine where interactions or physiological effects need to be weighed up individually. Our full Mounjaro side effects guide covers the broader safety picture, and the wider risks page goes into contraindications and cautions in more detail. If you have reviewed the evidence and want to explore whether treatment is suitable for you, our prescribers discuss exactly these questions as part of every free consultation.